SciSparc Ltd. (NASDAQ:SPRC) Short Interest Update

SciSparc Ltd. (NASDAQ:SPRCGet Free Report) saw a large drop in short interest during the month of November. As of November 15th, there was short interest totalling 260,200 shares, a drop of 33.6% from the October 31st total of 391,800 shares. Based on an average daily trading volume, of 1,010,000 shares, the days-to-cover ratio is presently 0.3 days. Approximately 2.5% of the shares of the company are sold short.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in SciSparc stock. Renaissance Technologies LLC acquired a new stake in SciSparc Ltd. (NASDAQ:SPRCFree Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 39,700 shares of the company’s stock, valued at approximately $32,000. Renaissance Technologies LLC owned 5.59% of SciSparc as of its most recent SEC filing. 25.06% of the stock is owned by institutional investors and hedge funds.

SciSparc Price Performance

Shares of SciSparc stock traded down $0.01 on Friday, hitting $0.21. The stock had a trading volume of 156,131 shares, compared to its average volume of 427,793. The business’s 50 day moving average is $0.23 and its two-hundred day moving average is $0.51. SciSparc has a twelve month low of $0.21 and a twelve month high of $9.80.

SciSparc Company Profile

(Get Free Report)

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.

Featured Articles

Receive News & Ratings for SciSparc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciSparc and related companies with MarketBeat.com's FREE daily email newsletter.